Table 3.

The effect of mepolizumab and reslizumab – continuate endpoints.

Absolute measures		Mepolizumab vs. placebo [95% CI]	Reslizumab vs. placebo [95% CI]	Mepolizumab vs. reslizumab [95% CI]
Lung function FEV1	Mean difference	99.11 [52.80; 145.41]	125.63 [76.73; 174.54]	−26.52 [−93.87; 40.83]
Asthma control questionnaire ACQ	Mean difference	−0.34 [−0.50; −0.19]	−0.26 [−0.34; −0.18]	−0.08 [−0.25; 0.09]
Quality of life (AQLQ and SGRQ)	SMD	0.33 [0.11; 0.55]	0.30 [0.18; 0.42]	0.03 [−0.22; 0.28]